A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

Exclusion Criteria

• •Have Type 1 diabetes mellitus
• •Have acute or chronic hepatitis, cirrhosis, or obvious clinical signs or symptoms of any other liver disease, except Nonalcoholic Fatty Liver Disease (NAFLD)
• •Estimated glomerular filtration rate (eGFR) \<20 milliliters/minute/1.73 square meter (m²)
• •Have active or untreated malignancy
• •Are pregnant
• •Have a significant weight gain or loss the past 3 months
• •Have received anytime in the past 6 months, any of the following insulin therapies:
• •* prandial insulin
• •* insulin mixtures
• •* inhaled insulin
• •* U-500 insulin, or
• •* continuous subcutaneous insulin infusion therapy
• •Have had any of New York Heart Association Class IV heart failure or any of the following CV conditions in the past 3 months:
• •* acute myocardial infarctions
• •* cerebrovascular accident (stroke), or
• •* coronary bypass surgery
• •Gastrointestinal: have undergone gastric bypass (bariatric) surgery, restrictive bariatric surgery (Lap-Band) or sleeve gastrectomy within 1 year prior to screening